晨光生物
(300138)
| 流通市值：44.73亿 | | | 总市值：54.25亿 |
| 流通股本：3.98亿 | | | 总股本：4.83亿 |
| 利润表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 营业总收入 | 1,628,953,634.09 | 6,559,043,728.38 | 5,047,254,465.57 | 3,657,547,726.71 |
| 营业总成本 | 1,521,636,644.31 | 6,178,716,674.03 | 4,718,060,635.45 | 3,432,495,143.03 |
| 其他经营收益 | | | | |
| 营业利润 | 113,658,573.3 | 436,359,595.5 | 368,695,457.16 | 263,968,367.45 |
| 利润总额 | 113,881,058.25 | 437,869,987.46 | 370,346,580.49 | 264,861,158.21 |
| 净利润 | 98,400,487.74 | 374,875,475.85 | 311,329,068.45 | 221,253,745.12 |
| 每股收益 | | | | |
| 其他综合收益 | -13,913,355.02 | -26,494,256.96 | -15,928,224.68 | -2,914,508.54 |
| 综合收益总额 | 84,487,132.72 | 348,381,218.89 | 295,400,843.77 | 218,339,236.58 |
| 资产负债表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 流动资产: | | | | |
| 流动资产合计 | 9,031,813,699.53 | 7,431,240,858.44 | 5,778,547,473.74 | 7,112,389,019.28 |
| 非流动资产: | | | | |
| 非流动资产合计 | 2,060,315,939.45 | 2,073,197,884.2 | 2,181,773,984.22 | 2,186,684,857.88 |
| 资产总计 | 11,092,129,638.98 | 9,504,438,742.64 | 7,960,321,457.96 | 9,299,073,877.16 |
| 流动负债: | | | | |
| 流动负债合计 | 7,292,676,052.05 | 5,782,438,648.52 | 4,164,742,425.23 | 5,589,174,757.48 |
| 非流动负债: | | | | |
| 非流动负债合计 | 275,979,521.64 | 283,013,161.57 | 408,292,022.14 | 399,673,716.28 |
| 负债合计 | 7,568,655,573.69 | 6,065,451,810.09 | 4,573,034,447.37 | 5,988,848,473.76 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 3,471,922,228.04 | 3,389,113,999.02 | 3,334,587,068.13 | 3,258,743,076.14 |
| 股东权益合计 | 3,523,474,065.29 | 3,438,986,932.55 | 3,387,287,010.59 | 3,310,225,403.4 |
| 负债和股东权益合计 | 11,092,129,638.98 | 9,504,438,742.64 | 7,960,321,457.96 | 9,299,073,877.16 |
| 现金流量表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 1,904,376,825.31 | 7,800,072,160.47 | 5,505,500,370.1 | 4,098,466,852.61 |
| 经营活动现金流出小计 | 1,627,516,146.63 | 7,587,165,191.48 | 3,168,940,641.19 | 2,268,730,213.27 |
| 经营活动产生的现金流量净额 | 276,860,678.68 | 212,906,968.99 | 2,336,559,728.91 | 1,829,736,639.34 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 664,848,754.68 | 894,220,433.33 | 3,620,753,610.68 | 1,793,627,155.66 |
| 投资活动现金流出小计 | 1,906,530,673.25 | 902,718,389.48 | 3,906,844,695.07 | 3,116,472,382.25 |
| 投资活动产生的现金流量净额 | -1,241,681,918.57 | -8,497,956.15 | -286,091,084.39 | -1,322,845,226.59 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 2,114,997,315.44 | 5,996,434,035.9 | 1,789,690,035.9 | 1,965,690,035.9 |
| 筹资活动现金流出小计 | 712,689,123.94 | 5,926,981,853.67 | 3,018,717,841.5 | 1,730,533,463.36 |
| 筹资活动产生的现金流量净额 | 1,402,308,191.5 | 69,452,182.23 | -1,229,027,805.6 | 235,156,572.54 |
| 汇率变动对现金及现金等价物的影响 | 1,217,453.22 | -3,622,724.59 | -4,979,642.25 | -2,226,398.82 |
| 现金及现金等价物净增加额 | 438,704,404.83 | 270,238,470.48 | 816,461,196.67 | 739,821,586.47 |
| 期末现金及现金等价物余额 | 1,223,745,115.33 | 785,040,710.5 | 1,331,263,436.69 | 1,254,623,826.49 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | 270,238,470.48 | - | 739,821,586.47 |
最新报告期：2026-07-29| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 国泰海通 | 林逸丹,王艳君 | 0.88 | 1.10 | 1.23 | 2026-07-29 |
| 长江证券 | 董思远,陈硕旸 | 0.88 | 1.16 | 1.32 | 2026-05-10 |